natgillin/translations-raw huggingface dataset:
The vaccine composition of claim 1, wherein the mineral oil is selected from the group consisting of paraffin oil, squalane, pristane, polyisobutene oil, hydrogenated polyisobutene oil, polydecene oil, polyisoprene oil, polyisopropene oil and, combinations thereof. 
Sastav cjepiva prema zahtjevu 1, naznačen time, da je mineralno ulje odabrano iz skupine koju čine parafinsko ulje, skualan, pristan, poliizobutensko ulje, hidrogenizirano poliizobutensko ulje, polidekensko ulje, poliizoprensko ulje, poliizopropensko ulje i njihove kombinacije.
The vaccine composition of claim 1, which comprises a paraffin oil, a sorbitan fatty acid monoester as a non-ionic lipophilic surfactant, an ethoxylated fatty acid triester of sorbitan as a low HLB non-ionic hydrophilic surfactant and a non-ionic block-copolymer as a high HLB non-ionic hydrophilic surfactant. 
Sastav cjepiva prema zahtjevu 1, naznačen time, da obuhvaća parafinsko ulje, monoester sorbitanske masne kiseline kao neionski lipofilni tenzid, etoksilirani triester masne kiseline od sorbitana kao neionski hidrofilni tenzid niske HLB-vrijednosti i neionski blok-kopolimer kao neionski hidrofilni tenzid visoke HLB-vrijednosti.
The vaccine composition of claim 9, wherein the sorbitan fatty acid monoester is a sorbitan monooleate, the ethoxylated fatty acid triester of sorbitan is an ethoxylated trioleate of sorbitan and the non-ionic block-copolymer is a polyoxyethylene/polyoxypropylene polymer (POE-POP). 
Sastav cjepiva prema zahtjevu 9, naznačen time, da monoester sorbitanske masne kiseline je sorbitan-monooleat, etoksilirani triester masne kiseline od sorbitana je etoksilirani trioleat od sorbitana i neionski blok-kopolimer je polioksietilen/polioksipropilen-polimer (POE-POP).
The vaccine composition of claim 11, wherein the paraffin oil is present at a concentration of 10% to 40% v/v, the sorbitan monooleate is present at a concentration of 0.2% to 1.5% w/v, the ethoxylated trioleate of sorbitan is present at a concentration of 2% to 5% w/v and the POE-POP is present at a concentration of 0.1% to 0.5%w/v; or the paraffin oil is present at a concentration of 29.3% v/v, the sorbitan monooleate is present at a concentration of 0.6% w/v, the ethoxylated trioleate of sorbitan is present at a concentration of 3.4% w/v and the POE-POP is present at a concentration of 0.25% w/v. 
Sastav cjepiva prema zahtjevu 11, naznačen time, da je parafinsko ulje prisutno u koncentraciji od 10% do 40% volumen/volumen, sorbitan-monooleat je prisutan u koncentraciji od 0,2% do 1,5% masa/volumen, etoksilirani trioleat od sorbitana je prisutan u koncentraciji od 2% do 5% masa/volumen i POE-POP je prisutan u koncentraciji od 0,1% do 0,5% masa/volumen; ili je parafinsko ulje prisutno u koncentraciji od 29,3% volumen/volumen, sorbitan-monooleat je prisutan u koncentraciji od 0,6% masa/volumen, etoksilirani trioleat od sorbitana je prisutan u koncentraciji od 3,4% masa/volumen i POE-POP je prisutan u koncentraciji od 0,25% masa/volumen.
The vaccine composition for the use according to claim 13, wherein the vaccine composition is to be administered by intramuscular (IM), intradermal (ID) or subcutaneous (SC) injection, or wherein the administration is done with a needleless injector. 
Sastav cjepiva za uporabu prema zahtjevu 13, naznačen time, da se sastav cjepiva primjenjuje pomoću intramuskularne (IM), intradermalne (ID) ili subkutane (SC) injekcije, ili se davanje cjepiva izvodi putem injektora bez igle.
A pharmaceutical composition comprising compound of formula IIB: or a pharmaceutically acceptable salt, solvate, stereoisomer and/or ester thereof, wherein: 
Farmaceutski sastav koji sadrži spoj formule IIB: [image] ili njegovu farmaceutski prihvatljivu sol, solvat, stereoizomer i/ili ester, gdje:
and R21, taken together with the nitrogen atom to which they are attached, form an unsubstituted or substituted 5-6 membered heterocyclyl ring containing 1-2 heteroatoms selected from the group consisting of N and O; 
i R21, zajedno sa atomom dušika za koji su vezani, formiraju nesupstituirani ili supstituirani 5-6-točlani heterociklil prsten koji sadrži 1-2 heteroatoma izabrana iz grupe koju čine N i O;
A compound of claim 1 having formula IIB, or a pharmaceutically acceptable salt, solvate, stereoisomer and/or ester thereof, wherein R13 is -(CH2)0-3CR17R18NR20R21, -(CH2)0-3CR17R18NR17C(O) NR20R21 or -(CH2)1-3-R23. 
Farmaceutski sastav prema patentnom zahtjevu 2, koji sadrži spoj formule IIB, ili njegovu farmaceutski prihvatljivu sol, solvat, stereoizomer i/ili ester, naznačeno time što R13 je -(CH2)0-3CR17R18NR20R21 ili -(CH2)0-3CR17R18NR17C(O)-NR20R21.
A compound of claim 1 of formula IIC: or a pharmaceutically acceptable salt, solvate, stereoisomer and/or ester thereof, wherein: 
Farmaceutski sastav prema zahtjevu 1, gdje spoj formule IIB spoj formule IIC: [image] ili njegova farmaceutski prihvatljiva sol, solvat, stereoizomer i/ili ester, gdje:
and R21, taken together with the nitrogen atom to which they are attached, form a 5-6 membered heterocyclyl ring containing 1-2 heteroatoms selected from the group consisting of N and O; 
i R21, zajedno sa atomom dušika za koji su vezani, formiraju 5-6 člani heterociklil prsten koji sadrži 1-2 heteroatoma izabrana iz grupe koju čine N i O;
The pharmaceutical composition of claim 1 wherein the compound of formula IIB is the compound of formula IIBa or a pharmaceutically acceptable salt, solvate, and/or ester thereof. 
Farmaceutski sastav prema zahtjevu 1, gdje je spoj formule IIB spoj formule IIBa [image] ili njegova farmaceutski prihvatljiva sol, solvat i/ili ester.
The pharmaceutical composition of claim 5, wherein the compound of formula IIB is the compound of formula IIBb or a pharmaceutically acceptable salt, solvate, and/or ester thereof. 
Farmaceutski sastav prema patentnom zahtjevu 5, gdje je spoj formule IIB spoj formule IIBb [image] ili njegova farmaceutski prihvatljiva sol, solvat i/ili ester.
A nanostructured organic-inorganic hybrid formulation crosslinkable by solar radiation, characterized by comprising at least one alkoxy-silane compound, trimethoxypropyl silane methacrylate, functionalized poly(dimethylsiloxane)-terminated vinyl, at least one methacrylic resin, a photoinitiator mixture containing at least one UV photoinitiator and at least one photoinitiator that can be activated by visible light. 
Nanostrukturirana organsko-anorganska hibridna formulacija koja se može umrežiti pomoću solarnog zračenja, naznačena time, da sadrži barem jedan alkoksi-silanov spoj, trimetoksipropilsilan metakrilat, funkcionalizirani poli(dimetilsiloksan) s vinilom na kraju, barem jednu metakrilnu smolu, smjesu fotoinicijatora koja sadrži barem jedan UV-fotoinicijator i barem jedan fotoinicijator koji se može aktivirati vidljivom svjetlosti.
The hybrid formulation according to claim 1 or 2, characterized in that the weight ratio of the UV photoinitiator to the photoinitiator that can activated by visible light in the photoinitiator mixture, is ranging from 0.5:10 to 0.5:20, preferably from 1:4 to 1:8, more preferably from 1:2 to 1:6. 
Hibridna formulacija prema patentnom zahtjevu 1 ili 2, naznačena time, da u smjesi fotoinicijatora, težinski omjer UV-fotoinicijatora prema fotoinicijatoru koji se može aktivirati vidljivom svjetlosti jest u području od 0,5:10 do 0,5:20, prvenstveno od 1:4 do 1:8, pogodnije od 1:2 do 1:6.
mixing an alkoxy-silane compound and trimethoxypropyl silane methacrylate with an organic solvent at an acidic pH, 
miješanje alkoksi-silanovog spoja i trimetoksipropilsilan metakrilata s organskim otapalom kod kiselog pH,
mixing the product obtained in step b) with a mixture obtained by methacrylic resin and a functionalized poly(dimethylsiloxane)-terminated vinyl, 
miješanje produkta dobivenog u stupnju b) sa smjesom dobivenom od metakrilne smole i funkcionaliziranog poli(dimetilsiloksana) s vinilom na kraju,
mixing 4-15% by weight of an alkoxy-silane compound, 20-85% by weight of trimethoxypropyl silane methacrylate with 1-4% by weight of an organic solvent at an acidic pH, 
miješanje 4-15 tež.% alkoksi-silanovog spoja, 20-85 tež.% trimetoksipropilsilan metakrilata s 1-4 tež.% organskog otapala kod kiselog pH,
hydrolyzing and condensing the mixture obtained in step a) with 20-30% by weight of water based on the alkoxy-silane compound content, 
hidroliziranje i kondenziranje smjese dobivene u stupnju a) s 20-30 tež.% vode, u odnosu na udio alkoksi-silanovog spoja,
mixing the product obtained in step b) with a mixture obtained by 5-60% by weight of a methacrylic resin and 2-5% by weight of a functionalized poly(dimethylsiloxane)-terminated vinyl, and 
miješanje produkta dobivenog u stupnju b) sa smjesom dobivenom od 5-60 tež.% metakrilne smole i 2-5 tež.% funkcionaliziranog poli(dimetilsiloksana) s vinilom na kraju.
The method according to claim 8 or 9, characterized in that the weight ratio of the UV photoinitiator to the photoinitiator that can be activated by visible light in the photoinitiator mixture, is ranging from 0.5:10 to 0.5:20, preferably from 1:4 to 1:8, more preferably from 1:2 to 1:6. 
Postupak prema patentnom zahtjevu 8 ili 9, naznačen time, da u smjesi fotoinicijatora, težinski odnos UV-fotoinicijatora prema fotoinicijatoru koji se može aktivirati vidljivom svjetlosti, jest u području od 0,5:10 do 0,5:20, prvenstveno od 1:4 do1:8, pogodnije od 1:2 do 1:6.
The cocrystal according to claim 1, wherein the amino acid is selected from the group consisting of L-valine and L-2-aminobutyric acid. 
Kokristal prema zahtjevu 1, gdje je aminokiselina odabrana iz skupine koju čine L-valin i L-2-aminomaslačna kiselina.
The cocrystal according to claim 3, which is (S)-2-hydroxy-3-methoxy-3,3-diphenylpropanoic acid - L-valine in a molar ratio 2:1. 
Kokristal prema zahtjevu 3, koji je (S)-2-hidroksi-3-metoksi-3,3-difenilpropan kiselina - L-valin u molarnom omjeru 2:1.
The cocrystal according to claim 4, which is characterized by having an X-ray powder diffractogram that comprises characteristic peaks at approximately 6.7, 12.4, 13.5, 16.2 and 18.9 degrees 2 theta at a Cu-Ka radiation, λ = 1.5406 Å. 
Kokristal prema zahtjevu 4, koji je naznačen time što ima difraktogram rendgenskog zračenja praška s karakterističnim vrhovima na oko 6.7, 12.4, 13.5, 16.2 i 18.9 stupnjeva 2 theta uz Cu-Ka zračenje, λ = 1.5406 Å.
The cocrystal according to claim 5, which is characterized by further comprising characteristic peaks in the X-ray powder diffractogram at approximately, 9.8, 16.0, 20.3, 25.6 and 32.5 degrees 2 theta at a Cu-Ka radiation, λ = 1.5406 Å. 
Kokristal prema zahtjevu 5, koji je naznačen time što dalje ima karakteristične vrhove difraktograma rendgenskog zračenja praška na oko 9.8, 16.0, 20.3, 25.6 i 32.5 stupnja 2 theta uz Cu-Ka zračenje, λ = 1.5406 Å.
The cocrystal according to claim 3, which is (S)-2-hydroxy-3-methoxy-3,3-diphenylpropanoic acid - L-2-aminobutyric acid in a molar ratio 2:1. 
Kokristal prema zahtjevu 3, koji je (S)-2-hidroksi-3-metoksi-3,3-difenilpropan kiselina - L-2-aminomaslačna kiselina u molarnom omjeru 2:1.
The cocrystal according to claim 7, which is characterized by having an X-ray powder diffractogram that comprises characteristic peaks at approximately 6.6, 6.7, 10.0, 13.3 and 16.3 degrees 2 theta at a Cu-Ka radiation, λ = 1.5406 Å. 
Kokristal prema zahtjevu 7, koji je naznačen time što ima difraktogram rendgenskog zračenja praška s karakterističnim vrhovima na oko 6.6, 6.7, 10.0, 13.3 i 16.3 stupnja 2 theta uz Cu-Ka zračenje, λ = 1.5406 Å.
The cocrystal according to claim 8, which is characterized by further comprising characteristic peaks in the X-ray powder diffractogram at approximately 10.3, 18.7, 20.1, 24.9 and 25.6 degrees 2 theta at a Cu-Ka radiation, λ = 1.5406 Å. 
Kokristal prema zahtjevu 8, koji je naznačen time što dalje ima karakteristične vrhove difraktograma rendgenskog zračenja praška na oko 10.3, 18.7, 20.1, 24.9 i 25.6 stupnjeva 2 theta uz Cu-Ka zračenje, λ = 1.5406 Å.
A process for preparing a cocrystal of (S)-2-hydroxy-3-methoxy-3,3-diphenylpropanoic acid and an amino acid as defined in any of the claims 1-9, comprising (a') mixing 2-hydroxy-3-methoxy-3,3-diphenylpropanoic acid and an amino acid in a mixture of (C1-C4)-alcohol/water at a temperature of from 40 °C to the reflux temperature of the solvent system used; 
Postupak pripreme kokristala (S)-2-hidroksi-3-metoksi-3,3-difenilpropan kiseline i aminokiseline kako je definirano prema bilo kojem od zahtjeva 1-9, koji obuhvaća (a’) miješanje 2-hidroksi-3-metoksi-3,3-difenilpropan kiseline i aminokiseline u smjesi (C1-C4)-alkohola/vode na temperaturi od 40°C do temperature refluksa korištenog sustava otapala;
A compound according to claim 1 or 2, wherein R1 is a nitrogen protecting group selected from pivaloyl, pyrrolidinylmethyl, t-butoxycarbonyl, benzyl, triethylsilyl, acetyl, benzyloxycarbonyl (Cbz) and trimethylsilyethoxymethyl (SEM). 
Spoj prema zahtjevu 1 ili 2, naznačen time, da R1 je dušikova zaštitna skupina odabrana od sljedećih: pivaloil, pirolidinilmetil, t-butoksikarbonil, benzil, trietilsilil, acetil, benziloksikarbonil (Cbz) i trimetilsilietoksimetil (SEM).
A process according to claim 8, comprising treating the compound of formula (1), or salt thereof, with a base and a methylating reagent, preferably treating the compound of formula (1-a), or salt thereof. A process according to claim 8, comprising: 
Postupak prema zahtjevu 8, naznačen time, da obuhvaća obradu spoja formule (1) ili njegove soli, s lužinom i metilacijskim reagensom, poželjno obuhvaća obradu spoja formule (1-a) ili njegove soli.
reacting the resulting compound of formula (20) with a base and a methylating reagent to obtain a compound of formula (20), or salt thereof, wherein R1 is hydrogen or a nitrogen protecting group, R11 is methyl and R10 is OR wherein R is alkyl, aryl or arylalkyl; 
reakcija dobivenog spoja formule (20) s lužinom i metilacijskim reagensom, kako bi se dobio spoj formule (20) ili njegova sol, pri čemu R1 je vodikova ili dušikova zaštitna skupina, R11 je metil i R10 je OR, dok R je alkil, aril ili arilalkil:
optionally, treating the compound of formula (20) wherein R1 is hydrogen or a nitrogen protecting group, R11 is methyl and R10 is OR wherein R is alkyl, aryl or arylalkyl, with a saponification reagent, to obtain a compound of formula (20), or salt thereof, wherein R1 is hydrogen or a nitrogen protecting group, R11 is methyl and R10 is OH; 
po izboru, obrada spoja formule (20) gdje R1 je vodikova ili dušikova zaštitna skupina, R11 je metil i R10 je OR, dok R je alkil, aril ili arilalkil, sa saponifikacijskim reagensom, kako bi se dobio spoj formule (20) ili njegova sol, gdje R1 je vodikova ili dušikova zaštitna skupina, R11 je metil i R10 je OH;
treating the compound obtained in step (b) or (c) under decarboxylation conditions to obtain the compound of formula (2). 
obrada spoja dobivenog u koraku (b) ili (c) pod dekarboksilacijskim uvjetima za dobivanje spoja formule (2).
A process for producing a compound according to formula (18) or a salt thereof comprising the steps 
Postupak za proizvodnju spoja u skladu sa sljedećom formulom (18) ili njegove soli:
providing a compound according to formula (1-a), or salt thereof, 
dobava spoja u skladu sa sljedećom formulom (1-a) ili njegove soli:
methylating the compound according to formula (1-a), or salt thereof, to obtain a compound according to formula (2-a), or salt thereof, 
metilacija spoja prema formuli (1-a) ili njegove soli, kako bi se dobio spoj u skladu sa sljedećom formulom (2-a) ili njegova sol:
reacting a compound according to formula (3-a) or a salt thereof to obtain a compound according to formula (18) or a salt thereof, 
reakcija spoja prema formuli (3-a) ili njegove soli, kako bi se dobio spoj u skladu s formulom (18) ili njegova sol;
wherein in the above formulae R1 and R2 are independently, of each other, hydrogen or a nitrogen protecting group and R3 is hydrogen or alkyl. 
pri čemu su R1 i R2 u gornjim formulama, međusobno neovisno vodikova ili dušikova zaštitna skupina i R3 je vodik ili alkil.
reacting the compound according to formula (4), or salt thereof, with a biphenylic compound to obtain a compound according to formula (5), or salt thereof, wherein R1 is hydrogen or a nitrogen protecting group and 
reakcija spoja prema formuli (4) ili njegove soli, s bifenilnim spojem, kako bi se dobio spoj u skladu sa sljedećom formulom (5) ili njegova sol: [image] gdje R1 je vodikova ili dušikova zaštitna skupina; i
reducing a compound according to formula (5), or salt thereof, to obtain a compound according to formula (1), or salt thereof. 
redukcija spoja prema formuli (5) ili njegove soli, kako bi se dobio spoj u skladu s formulom (1) ili njegova sol.
A process according to claim 22, wherein the CO-activating group is selected from dimethylamino, morpholinyl, imidazolyl, methylmethoxyamino, -O-methyl, -O-ethyl, chloro, bromo, pivaloyl and acetyl. 
Postupak prema zahtjevu 22, naznačen time, da CO-aktivacijska skupina je odabrana iz skupine koju čine: dimetilamino, morfolinil, imidazolil, metilmetoksiamino, -O-metil, -O-etil, klor, brom, pivaloil i acetil.
providing a compound according to formula (7), or salt thereof, wherein R1 and R2 are independently, of each other, hydrogen or a nitrogen protecting group, 
dobava spoja u skladu sa sljedećom formulom (7) ili njegove soli: [image] gdje su R1 i R2 međusobno neovisno vodikova ili dušikova zaštitna skupina,
reacting a compound according to formula (7), or salt thereof, in a Wittig reaction to obtain a compound according to formula (8), or salt thereof, wherein R1 and R2 are independently, of each other, hydrogen or a nitrogen protecting group and R5 is hydrogen or alkyl, 
reakcija spoja prema formuli (7) ili njegove soli, u Wittigovoj reakciji, kako bi se dobio spoj u skladu sa sljedećom formulom (8) ili njegova sol: [image] gdje su R1 i R2 međusobno neovisno vodikova ili dušikova zaštitna skupina i R5 je vodik ili alkil,
reducing a compound according to formula (8), or salt thereof, to obtain a compound according to formula (9), or salt thereof, wherein R1 and R2 are independently, of each other, hydrogen or a nitrogen protecting group and R5 is hydrogen or alkyl, optionally removing the nitrogen protecting groups, thereby obtaining a compound according to formula (10) or a salt thereof wherein R5 is hydrogen or alkyl, and 
redukcija spoja prema formuli (8) ili njegove soli, kako bi se dobio spoj u skladu sa sljedećom formulom (9) ili njegova sol: [image] gdje su R1 i R2 međusobno neovisno vodikova ili dušikova zaštitna skupina i R5 je vodik ili alkil, po izboru, odstranjivanje dušikovih zaštitnih skupina, čime se dobiva spoj u skladu sa sljedećom formulom (10) ili njegova sol:
reacting the compound according to formula (10), or salt thereof, wherein R5 is hydrogen or alkyl, under ring-closing conditions to obtain a compound according to formula (1), or salt thereof. 
reakcija spoja prema formuli (10) ili njegove soli, pri čemu R5 je vodik ili alkil, pod uvjetima zatvaranja prstena, kako bi se dobio spoj u skladu s formulom (1) ili njegova sol.
A process for preparing a compound according to formula (1), or salt thereof, wherein R1 is hydrogen or a nitrogen protecting group, comprising reacting a compound according to formula (11), or salt thereof, wherein R1 is hydrogen or a nitrogen protecting group and R6 is a leaving group, with an activated biphenylic compound. 
[image] gdje R1 je vodikova ili dušikova zaštitna skupina, naznačen time, da obuhvaća rekciju spoja u skladu sa sljedećom formulom (11) ili njegove soli: [image] gdje R1 je vodikova ili dušikova zaštitna skupina i R6 je izlazna skupina, s aktiviranim bifenilnim spojem.
A process according to claim 33 or 34, wherein the reaction of the compound of formula (11) with an activated biphenylic compound takes place under Fe- or Mn-catalyzed cross coupling reaction conditions. 
Postupak prema zahtjevu 33 ili 34, naznačen time, da se reakcija spoja formule (11) s aktiviranim bifenilnim spojem, izvodi pod reakcijskim uvjetima Fe-kataliziranog ili Mn-kataliziranog križnog spajanja.
A process according to claim 35, wherein the reaction of the compound of formula (11) with an activated biphenylic compound takes place by the use of FeCl3, Fe(acac)3 or MnCl2. 
Postupak prema zahtjevu 35, naznačen time, da se reakcija spoja formule (11) s aktiviranim bifenilnim spojem, izvodi uz pomoć uporabe FeCl3, Fe(acac)3 ili MnCk
A process according to claim 33 or 34, wherein the reaction of the compound of formula (11) with an activated biphenylic compound takes place in the presence of a metal salt additive. 
Postupak prema zahtjevu 33 ili 34, naznačen time, da se reakcija spoja formule (11) s aktiviranim bifenilnim spojem, izvodi u prisutnosti metalne soli kao aditiva.
reacting the compound according to formula (12), or salt thereof, with an activated (e.g. metallated) biphenylic compound to obtain a compound according to formula (13), or salt thereof, wherein R1 is hydrogen or a nitrogen protecting group, and 
[image] gdje R1 je vodikova ili dušikova zaštitna skupina, reakcija spoja prema formuli (12) ili njegove soli, s aktiviranim (naime metaliranim) bifenilnim spojem, kako bi se dobio spoj u skladu sa sljedećom formulom (13) ili njegova sol:
reducing the compound according to formula (13), or salt thereof, to obtain the compound according formula (1), or salt thereof. 
redukcija spoja prema formuli (13) ili njegove soli, kako bi se dobio spoj u skladu s formulom (1) ili njegova sol.
reacting the compound according to formula (14), or salt thereof, with 4-formyl biphenyl to obtain a compound according to formula (15), or salt thereof, 
reakcija spoja prema formuli (14) ili njegove soli, s 4-formil-bifenilom, kako bi se dobio spoj u skladu sa sljedećom formulom (15) ili njegova sol:
reducing the compound according to formula (16), or salt thereof, to obtain a compound according to formula (1), or salt thereof, 
redukcija spoja prema formuli (16) ili njegove soli, kako bi se dobio spoj u skladu s formulom (1) ili njegova sol;
wherein in formulae (14) to (16) R1 is hydrogen or a nitrogen protecting group. 
pri čemu u formulama od (14) do (16), R1 je vodikova ili dušikova zaštitna skupina.
wherein in formulae (14) and (15) R1 is hydrogen or a nitrogen protecting group. 
pri čemu u formulama (14) i (15), R1 je vodikova ili dušikova zaštitna skupina.
A process according to claim 54 wherein the configuration of compound (16), or salt thereof, is according to formula (16-a) wherein R1 is hydrogen or a nitrogen protecting group. 
Postupak prema zahtjevu 54, naznačen time, da je konfiguracija spoja formule (16) ili njegove soli, u skladu sa sljedećom formulom (16-a): [image] gdje R1 je vodikova ili dušikova zaštitna skupina.
A process for preparing a compound according to formula (15), or salt thereof, wherein R1 is hydrogen or a nitrogen protecting group, comprising reacting a compound according to formula (17), or salt thereof, wherein R1 is hydrogen or a nitrogen protecting group, with an organometallic reagent derived from 4-methyl biphenyl to obtain a compound according to formula (15), or salt thereof. 
[image] gdje R1 je vodikova ili dušikova zaštitna skupina, naznačen time, da obuhvaća reakciju spoja u skladu sa sljedećom formulom (17) ili njegove soli: [image] gdje R1 je vodikova ili dušikova zaštitna skupina, s organometalnim reagensom izvedenim iz 4-metil-bifenila, kako bi se dobio spoj u skladu s formulom (15) ili njegova sol.
The use according to claim 57, wherein the compound, or salt thereof, has a configuration according to formula (1-a) wherein R1 is hydrogen or a nitrogen protecting group. 
Uporaba prema zahtjevu 57, naznačena time, da spoj ili njegova sol ima konfiguraciju u skladu sa sljedećom formulom (1-a): [image] gdje R1 je vodikova ili dušikova zaštitna skupina.
A compound according to claim 60, wherein in formula (2-a) R1 is hydrogen or a nitrogen protecting group selected from pivaloyl and t-butyloxycarbonyl (BOC). 
Spoj prema zahtjevu 60, naznačen time, da u formuli (2-a), R1 je vodikova ili dušikova zaštitna skupina odabrana od pivaloila i t-butiloksikarbonila (BOC).